TRPC6 and breast carcinoma: A recent study on breast cancer MCF-7 and MDA-MB-231 cells showed that the surface expression of Orai1 and Orai3, as well as the subsequent Ca2+ influx, was significantly reduced by overexpressing the dominant-negative mutant, or silencing, of the canonical transient receptor potential 6 (TRPC6) [154], implying the feasibility of targeting TRPC6 for cancer therapy.